Literature DB >> 21062909

Carisoprodol legal status and patterns of abuse.

Jennifer A Fass1.   

Abstract

OBJECTIVE: To review the current legal status and patterns of abuse of carisoprodol. DATA SOURCES: A literature search was conducted through MEDLINE (1950-August 2010), PubMed (1966-August 2010), EMBASE (1966-August 2010), and International Pharmaceutical Abstracts (1970-August 2010) using the search terms carisoprodol and abuse. In addition, reference citations from publications identified were reviewed. State laws and regulations were accessed through NABPLAW Online (2010) using the search term carisoprodol. Federal proposed rules were accessed through the Federal Register (1995 Volume 59-2010 Volume 75) using the search term carisoprodol. STUDY SELECTION AND DATA EXTRACTION: State laws and federal proposed rules regarding carisoprodol were examined. Case reports and studies involving carisoprodol abuse were evaluated. DATA SYNTHESIS: Carisoprodol is not federally scheduled under the Controlled Substances Act (CSA). However, carisoprodol is scheduled in 36% (n = 18) of states of the US. The Drug Enforcement Administration issued a Notice of Proposed Rulemaking in the Federal Register on November 17, 2009, to place carisoprodol into schedule IV of the CSA, with a deadline to submit written comments by December 17, 2009. Case reports, retrospective studies, and national reports, including reports from the American Association of Poison Control Centers and results from the Monitoring the Future national survey on drug use, have identified carisoprodol's abuse potential.
CONCLUSIONS: Carisoprodol should be placed in schedule IV of the CSA based on its abuse potential and current state laws and regulations. Federally scheduling carisoprodol would lead to uniformity among the states and hopefully assist in preventing prescription drug abuse. Larger, well-designed studies evaluating carisoprodol abuse should be performed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21062909     DOI: 10.1345/aph.1P339

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  7 in total

1.  Carisoprodol pharmacokinetics and distribution in the nucleus accumbens correlates with behavioral effects in rats independent from its metabolism to meprobamate.

Authors:  Theresa M Carbonaro; Vien Nguyen; Michael J Forster; Michael B Gatch; Laszlo Prokai
Journal:  Neuropharmacology       Date:  2020-05-29       Impact factor: 5.250

2.  Characterizing the subjective and psychomotor effects of carisoprodol in healthy volunteers.

Authors:  James P Zacny; Judith A Paice; Dennis W Coalson
Journal:  Pharmacol Biochem Behav       Date:  2011-08-23       Impact factor: 3.533

3.  Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain.

Authors:  Corey Witenko; Robin Moorman-Li; Carol Motycka; Kevin Duane; Juan Hincapie-Castillo; Paul Leonard; Christopher Valaer
Journal:  P T       Date:  2014-06

4.  Carisoprodol tolerance and precipitated withdrawal.

Authors:  Michael B Gatch; Jacques D Nguyen; Theresa Carbonaro; Michael J Forster
Journal:  Drug Alcohol Depend       Date:  2011-11-04       Impact factor: 4.492

5.  Assessment of subunit-dependent direct gating and allosteric modulatory effects of carisoprodol at GABA(A) receptors.

Authors:  Manoj Kumar; Lorie A González; Glenn H Dillon
Journal:  Neuropharmacology       Date:  2015-04-18       Impact factor: 5.250

6.  Subjective and psychomotor effects of carisoprodol in combination with oxycodone in healthy volunteers.

Authors:  James P Zacny; Judith A Paice; Dennis W Coalson
Journal:  Drug Alcohol Depend       Date:  2011-08-15       Impact factor: 4.492

7.  A Single Amino Acid Residue at Transmembrane Domain 4 of the α Subunit Influences Carisoprodol Direct Gating Efficacy at GABAA Receptors.

Authors:  Manoj Kumar; Manish Kumar; John M Freund; Glenn H Dillon
Journal:  J Pharmacol Exp Ther       Date:  2017-06-22       Impact factor: 4.030

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.